8-K: Predictive Oncology Pivots to Digital Assets with $344M Raise

Predictive Oncology Inc. announced two private placements totaling $344.4 million to fund a new digital asset treasury strategy focused on Aethir (ATH) tokens, alongside its existing AI drug discovery business.

Summary

• Predictive Oncology Inc. (POAI) is adopting a digital asset treasury strategy, with Aethir (ATH) tokens as the principal holding, while continuing its artificial intelligence and machine learning business for drug discovery.
• The company announced two private placement transactions (PIPEs) to raise an aggregate of approximately $344.4 million.
• The Cash PIPE will raise approximately $51.7 million from the sale of 66.7 million shares of common stock (or pre-funded warrants) at $0.7751 per share.
• The Crypto PIPE involves pre-funded warrants to purchase up to 223.6 million shares of common stock, valued at a notional $292.7 million (discounted value of $173.3 million), in exchange for in-kind contributions of locked and unlocked Aethir tokens.
• The pre-funded warrants from the Crypto PIPE will become exercisable upon shareholder approval.
• The PIPEs are expected to close concurrently on or about October 2, 2025, subject to customary closing conditions.
• Proceeds from the in-kind ATH contribution will fund the digital asset treasury strategy, and remaining net cash proceeds will primarily fund open market acquisition of ATH, as well as working capital and general corporate purposes.
• DNA Holdings Venture, Inc. will serve as the strategic advisor for the digital asset treasury and its CEO, Shawn Matthews, will join the Board of Directors upon closing.
• Aethir operates a decentralized GPU network with 435,000 GPU containers across 200+ locations, offering enterprise-grade AI infrastructure with significant cost savings.
• For each ATH token purchased by the company on the open market, the DCI Foundation will grant an additional 20% of the purchased ATH tokens.
• The company's stockholders approved a 1-for-15 reverse stock split, effective 12:01 a.m. on September 30, 2025; all share and price information in the press release is pre-split.

Sentiment

Score: 7

Explanation: The company has secured a significant capital raise and is embarking on a bold strategic pivot into the high-growth, but volatile, digital asset and AI infrastructure sector. This move introduces substantial new opportunities for growth and diversification, while also carrying inherent risks associated with market volatility and regulatory uncertainty in the digital asset space. The continued commitment to its core AI drug discovery business provides a foundation, but the new strategy represents a transformative shift.

Positives

• Secured a substantial capital raise of approximately $344.4 million, significantly bolstering the company's financial position.
• Embarking on a new growth opportunity in the rapidly expanding digital asset and AI infrastructure sector through its digital asset treasury strategy.
• Partnership with Aethir, a leading decentralized GPU network, provides access to high-demand AI compute resources and potential for a 'Strategic Compute Reserve'.
• The DCI Foundation's grant of an additional 20% ATH tokens for open market purchases enhances the company's digital asset holdings.
• Appointment of Shawn Matthews, former CEO of Cantor Fitzgerald and CEO of DNA Holdings, to the Board of Directors brings significant financial and strategic expertise.
• The company continues to execute on its core artificial intelligence and machine learning business for early drug discovery and development.

Negatives

• Significant strategic pivot introduces exposure to the highly volatile and speculative digital asset market, which carries inherent risks of price fluctuations and potential loss.
• The exercise of pre-funded warrants from the Crypto PIPE is contingent on shareholder approval, introducing uncertainty.
• The valuation of the Crypto PIPE involves a 'notional value' versus a 'discounted value', which may require further clarification for investors.
• The reverse stock split (1-for-15) often indicates a need to maintain Nasdaq listing requirements and can sometimes be perceived negatively by the market.

Risks

• The proposed private placements and related transactions may not be completed in a timely manner or at all.
• Failure to realize the anticipated benefits of the private placement and the proposed digital asset treasury strategy.
• Economic conditions and their impact on the company's operations and financial performance.
• Fluctuations in the market price of ATH and other digital assets, leading to potential impairment of treasury holdings.
• The impact of the evolving regulatory environment on the company's digital asset strategy and operations.
• The ability of the company to effectively execute on its digital asset treasury strategy and its implications for shareholders and the core business.
• The ability of the Aethir ecosystem to perform in a manner consistent with projections and deliver expected utility.
• Failure to receive shareholder approval for the exercise of the pre-funded warrants issued in connection with the Crypto PIPE and related matters.
• General market and other conditions affecting the company's business and the value of its assets.

Future Outlook

The company intends to continue pursuing its current lines of business in artificial intelligence and machine learning for drug discovery, in addition to its new digital asset treasury strategy. The digital asset strategy will primarily involve acquiring and managing ATH tokens to establish the world's first Strategic Compute Reserve, functioning as an operator on the Aethir ecosystem to strengthen global AI infrastructure. Net proceeds from the PIPEs will fund ATH acquisitions, working capital, and general corporate purposes.

Management Comments

• Raymond Vennare, CEO and Chairman of the Board of Predictive Oncology: "Our partnership with Aethir represents a seminal event for Predictive Oncology and we believe it creates an outstanding opportunity for the Company and our shareholders to solidify and expand our core business while embarking upon an incremental growth opportunity through our digital asset treasury strategy."
• Raymond Vennare, CEO and Chairman of the Board of Predictive Oncology: "With the planned adoption of the Companys digital asset strategy, we will be able to establish the worlds first Strategic Compute Reserve."
• Dan Wang, Co-Founder and CEO of Aethir: "The Company will act not just as a digital asset treasury, but through its planned holdings of ATH, it will be able to function as an operator on the Aethir ecosystem that we believe will strengthen Aethirs ability to provide the global infrastructure layer for the future of AI."

Industry Context

This announcement positions Predictive Oncology at the intersection of biotechnology, artificial intelligence, and the rapidly evolving decentralized physical infrastructure network (DePIN) sector. The move into digital assets, specifically Aethir's decentralized GPU network, aligns with the increasing global demand for AI compute resources. By leveraging Aethir's infrastructure, the company aims to capitalize on the trend towards more cost-effective and rapidly deployable AI infrastructure, potentially disrupting traditional cloud computing models.

Comparison to Industry Standards

• Aethir's decentralized GPU network offers enterprise-grade AI infrastructure with approximately 40-80% cost savings compared to traditional and neocloud providers, such as AWS and Google Cloud.
• Aethir enables rapid deployment of AI workloads (24-48 hours instead of months), providing a significant advantage over conventional infrastructure provisioning.

Management Changes

Related Party Transactions

• DNA Holdings Venture Inc. is acting as the strategic advisor and consultant for the company's digital asset treasury strategy.
• DNA Holdings Venture Inc. is also an investor in the Cash PIPE.

Stakeholder Impact

• Shareholders: Potential for significant value creation from the new digital asset strategy, but also increased exposure to cryptocurrency market volatility and potential dilution from warrant exercises. The reverse stock split will reduce the number of outstanding shares.
• Employees: Continued focus on the core AI/ML business, with potential for new roles or strategic shifts related to the digital asset treasury.
• Customers: Continued access to the company's AI-based drug discovery solutions, with potential for future integration or benefits from the new AI infrastructure capabilities.
• Creditors: Improved financial stability due to the substantial capital raise, potentially enhancing the company's ability to meet its obligations.

Next Steps

• The two private placement transactions (PIPEs) are expected to close concurrently on or about October 2, 2025.
• Shawn Matthews is expected to join the Board of Directors upon the closing of the private placements.
• The company will use net proceeds to acquire ATH tokens in the open market to support its digital asset treasury strategy.
• The company will seek shareholder approval for the exercise of the pre-funded warrants issued in the Crypto PIPE.
• The company will continue to pursue its current lines of business in artificial intelligence and machine learning for drug discovery.

Key Dates

Recommendation

The company is undergoing a significant strategic pivot by entering the digital asset treasury space, specifically focusing on Aethir (ATH) tokens, while simultaneously raising substantial capital. This introduces a new, high-growth, but also high-risk, dimension to its business model. While the capital raise strengthens the balance sheet and the digital asset strategy offers potential for significant returns in the AI infrastructure sector, it also exposes the company to the inherent volatility and regulatory uncertainties of the cryptocurrency market. Existing investors should hold to observe the execution and integration of this new strategy and its impact on the core AI drug discovery business. New investors should approach with caution, weighing the speculative upside against the increased risk profile.

Keywords

Predictive Oncology, POAI, Aethir, ATH, Digital Asset Treasury, AI Infrastructure, GPU as a Service, Decentralized GPU Network, Private Placement, PIPE, Artificial Intelligence, Machine Learning, Drug Discovery, Biotechnology, Cryptocurrency, DePIN